oxybutynin has been researched along with Allergic Contact Dermatitis in 11 studies
oxybutynin: RN given refers to parent cpd
oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To characterize the profile of application site reactions (ASRs) for patients treated with the buprenorphine transdermal system (BTDS) in chronic pain studies." | 3.79 | Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis. ( Lynch, SY; Maibach, H; Munera, C; Ripa, SR; Swanton, R; Wen, W, 2013) |
| " Rivastigmine, a cholinesterase inhibitor, is commonly used as a treatment for dementia due to its ability to moderate cholinergic neurotransmission; however, treatment with oral rivastigmine can lead to gastrointestinal adverse effects such as nausea and vomiting." | 2.47 | Transdermal rivastigmine: management of cutaneous adverse events and review of the literature. ( Adam, DN; Greenspoon, J; Herrmann, N, 2011) |
| "Using Medline, Embase, and the Science Citation Index, we summarize the cutaneous adverse effects of transdermal and parenteral fentanyl." | 2.46 | Fentanyl transdermal patches: overview of cutaneous adverse effects in humans. ( Hostynek, JJ; Maibach, HI, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (81.82) | 24.3611 |
| 2020's | 2 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Asano, A | 1 |
| Nakai, K | 1 |
| Tsuruta, D | 1 |
| Olthoff, MV | 1 |
| Kunkeler, ACM | 1 |
| van Hunsel, FPAM | 1 |
| Beekwilder, JMA | 1 |
| Borgsteede, SD | 1 |
| Navarro-Triviño, FJ | 1 |
| Ruiz-Villaverde, R | 1 |
| Oppel, E | 1 |
| Högg, C | 1 |
| Summer, B | 1 |
| Ruëff, F | 1 |
| Reichl, FX | 1 |
| Kamann, S | 1 |
| Romita, P | 1 |
| Foti, C | 1 |
| Calogiuri, G | 1 |
| Cantore, S | 1 |
| Ballini, A | 1 |
| Dipalma, G | 1 |
| Inchingolo, F | 1 |
| Wen, W | 1 |
| Lynch, SY | 1 |
| Munera, C | 1 |
| Swanton, R | 1 |
| Ripa, SR | 1 |
| Maibach, H | 1 |
| Raison-Peyron, N | 1 |
| Guillot, B | 1 |
| Liu, DJ | 1 |
| Collaku, A | 1 |
| Dosik, JS | 1 |
| Hostynek, JJ | 1 |
| Maibach, HI | 1 |
| Alfaya, T | 1 |
| Mur Gimeno, P | 1 |
| Iglesias, AM | 1 |
| Ventura, P | 1 |
| Greenspoon, J | 1 |
| Herrmann, N | 1 |
| Adam, DN | 1 |
3 reviews available for oxybutynin and Allergic Contact Dermatitis
| Article | Year |
|---|---|
Contact dermatitis due to transdermal therapeutic systems: a clinical update.
Topics: Adhesives; Allergens; Dermatitis, Allergic Contact; Dermatitis, Irritant; Diagnosis, Differential; D | 2018 |
Fentanyl transdermal patches: overview of cutaneous adverse effects in humans.
Topics: Analgesics, Opioid; Dermatitis, Allergic Contact; Dermatitis, Irritant; Erythema; Female; Fentanyl; | 2010 |
Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Topics: Administration, Cutaneous; Alzheimer Disease; Cholinesterase Inhibitors; Dermatitis, Allergic Contac | 2011 |
1 trial available for oxybutynin and Allergic Contact Dermatitis
| Article | Year |
|---|---|
Skin Irritation and Sensitization Potential of Fixed-Dose Combination of Diclofenac 1% and Menthol 3% Topical Gel: Results of Two Phase I Patch Studies.
Topics: Administration, Cutaneous; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non | 2017 |
7 other studies available for oxybutynin and Allergic Contact Dermatitis
| Article | Year |
|---|---|
Lichenoid drug eruption associated with bisoprolol transdermal patches.
Topics: Administration, Cutaneous; Adrenergic beta-1 Receptor Antagonists; Bisoprolol; Delayed-Action Prepar | 2022 |
[Hypersensitivity reactions to excipients in patches].
Topics: Angioedema; Dermatitis, Allergic Contact; Excipients; Female; Humans; Male; Skin Tests; Transdermal | 2019 |
Allergic contact dermatitis caused by 2-ethylhexyl acrylate in a rivastigmine transdermal therapeutic system.
Topics: Acrylates; Adhesives; Aged, 80 and over; Cholinesterase Inhibitors; Dermatitis, Allergic Contact; Hu | 2020 |
Isobornyl acrylate contained in the insulin patch pump OmniPod as the cause of severe allergic contact dermatitis.
Topics: Acrylates; Administration, Cutaneous; Camphanes; Child; Dermatitis, Allergic Contact; Humans; Hypogl | 2018 |
Application site adverse events associated with the buprenorphine transdermal system: a pooled analysis.
Topics: Administration, Cutaneous; Aged; Buprenorphine; Chronic Pain; Clinical Trials, Phase III as Topic; D | 2013 |
Allergic contact dermatitis caused by rotigotine in a transdermal therapeutic system.
Topics: Administration, Cutaneous; Aged; Dermatitis, Allergic Contact; Dopamine Agonists; Humans; Parkinson | 2016 |
Allergic contact dermatitis caused by an ethinylestradiol-norelgestromin transdermal therapeutic system.
Topics: Contraceptive Agents, Female; Dermatitis, Allergic Contact; Ethinyl Estradiol-Norgestrel Combination | 2011 |